Nuzenio

Maintains Ideaya Biosciences

Maintains Ideaya Biosciences news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 3 publisher sources 100/100 entity strength

Latest news

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - MoomooMoomoo · Sun, 09 Aug 2026 11:18:08 GMTIdeaya Biosciences price target lowered to $42 from $45 at Citizens - TipRanksTipRanks · Thu, 06 Aug 2026 23:13:05 GMTIdeaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05) - TipRanksTipRanks · Wed, 05 Aug 2026 07:05:44 GMTUveal melanoma trial reports 6.9 months progression-free vs. 3.1 - Stock TitanStock Titan · Tue, 04 Aug 2026 10:00:00 GMT

Timeline

Sun, 09 Aug 2026 11:18:08 GMTLifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Thu, 06 Aug 2026 23:13:05 GMTIdeaya Biosciences price target lowered to $42 from $45 at Citizens - TipRanks
Wed, 05 Aug 2026 07:05:44 GMTIdeaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05) - TipRanks
Tue, 04 Aug 2026 10:00:00 GMTUveal melanoma trial reports 6.9 months progression-free vs. 3.1 - Stock Titan

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Maintains Ideaya Biosciences.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.